A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Registration Number
- JPRN-jRCT2031230201
- Lead Sponsor
- Masaki Takeshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 260
Are candidates for systemic therapy.
ISA specific:
Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit:
EASI score greater than or equal to (>=)16
vIGA-AD score >=3, and
>=10% of BSA involvement (per EASI BSA).
Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.
ISA specific:
Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB.
Are currently being treated with topical or systemic therapy
Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75 [ Time Frame: Week 16 ]
- Secondary Outcome Measures
Name Time Method